Xingang Pharmaceutical
Xingang Pharmaceutical Co., Ltd., commonly referred to as Xingang Pharma, is a prominent player in the pharmaceutical industry, headquartered in China (CN). Established in 2001, the company has made significant strides in the development and manufacturing of high-quality pharmaceutical products, particularly in the fields of generic drugs and active pharmaceutical ingredients (APIs). With a strong operational presence across Asia and expanding into global markets, Xingang Pharma is recognised for its commitment to innovation and quality. The company’s core offerings include a diverse range of medications that cater to various therapeutic areas, setting them apart through rigorous quality control and adherence to international standards. Xingang Pharma has achieved notable milestones, positioning itself as a trusted name in the industry, and continues to enhance its market presence through strategic partnerships and a focus on research and development.
DitchCarbon Score
How does Xingang Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Xingang Pharmaceutical's score of 15 is lower than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Xingang Pharmaceutical's reported carbon emissions
In 2023, Xingang Pharmaceutical, headquartered in China (CN), has set ambitious climate commitments, aiming for a 90% reduction in absolute carbon emissions for Scopes 1 and 2 by 2050, using 2023 as the base year. This long-term target reflects the company's commitment to sustainability and aligns with industry standards for climate action. The most recent emissions data available indicates that in 2019, Xingang Pharmaceutical reported Scope 1 emissions of approximately 93,013,650 kg CO2e and Scope 2 emissions of about 151,030 kg CO2e. This data highlights the company's significant carbon footprint, which they are actively working to reduce. Xingang Pharmaceutical has not disclosed specific emissions data for 2020 to 2022, but they have reported GHG emissions per RMB10,000 of revenue, showing a gradual decrease from 0.000017 kg CO2e in 2021 to 0.000018 kg CO2e in 2020, and 0.000018 kg CO2e in 2022. This trend suggests ongoing efforts to improve efficiency and reduce emissions relative to revenue. The company's climate commitments are not cascaded from a parent organisation, indicating that these targets and data are independently established. As they work towards their long-term goals, Xingang Pharmaceutical is positioning itself as a responsible player in the pharmaceutical industry, committed to reducing its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | |
|---|---|---|---|
| Scope 1 | 64,953,440 | 00,000,000 | 00,000,000 |
| Scope 2 | 235,360 | 00,000 | 000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Xingang Pharmaceutical is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
